Bio-Rad Laboratories BIO Total Liabilities & Equity
Total Liabilities & Equity at other companies
Other financials
Where this comes from
Reported directly by Bio-Rad Laboratories in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: Bio-Rad Laboratories’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bio-Rad Laboratories's total liabilities & equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bio-Rad Laboratories's total liabilities & equity?
- Bio-Rad Laboratories (BIO) reported total liabilities & equity of $9.79B in Q1 2026.
- How has Bio-Rad Laboratories's total liabilities & equity changed year-over-year?
- Bio-Rad Laboratories's total liabilities & equity increased by 2.8% year-over-year, from $9.53B to $9.79B.
- What is the long-term trend for Bio-Rad Laboratories's total liabilities & equity?
- Over 5 years (2020 to 2025), Bio-Rad Laboratories's total liabilities & equity has grown at a -4.0% compound annual growth rate (CAGR), from $12.97B to $10.58B.
- What does total liabilities & equity mean?
- The sum of all money owed to creditors and the total value belonging to shareholders.
- How do you interpret total liabilities & equity?
- An increase indicates growth in the company's asset base funded by either debt or equity, while a decrease suggests a contraction in the scale of operations or asset base.
- How does total liabilities & equity compare across companies?
- Standardized across all public companies as the total size of the balance sheet.